7 min read

Discover how Private Equity is transforming life sciences: revolutionizing R&D, redefining supply chains, and driving innovation for a healthier future Uncharted waters — this metaphor aptly describes today’s life sciences investment landscape. Private equity (PE) is a trailblazer, rewriting the rules with bold moves and strategic insights. It’s a realm where Platinum Equity’s acquisition of LifeScan symbolizes a strategic leap in digital health. This move, coupled with Blackstone, The Carlyle Group, and Hellman & Friedman’s transformative investment in Medline, marks a new epoch in medical supply innovation. Goldman Sachs’ bold 1.8 billion euros maneuver to acquire Norgine BV further cements PE’s influence in the sector. Over……

This article is free to read

Login to read the full article


OR

By subscribing to our main site, you will also be subscribed to DDIntel – our regular letter showcasing our featured articles and applications.

Flavio Aliberti

Flavio Aliberti brings with him a 22-year track record in consulting around business intelligence, change management, strategy, M&A transformation, IT and SOX auditing for high regulated domains, like Insurance, Airlines, Trade Associations, Automotive, and Pharma. He holds an MSc in Space Aeronautic Engineering from the University of Naples and an MSc in Advanced Information Technology and Business Management from the University of Wales.

End

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.

To Get The Latest News Update

Sign up to Our Subscription.

We don’t spam! Read our privacy policy for more info.